Bullish reversal indicators.
Increasing volume with solid support, as GALT enters 2021 catalysts.
GALT
Due Diligence Cliff's Notes:
— Leading inhibitor under development for Galectin-3, key native immune system protein involved in numerous inflammatory and fibrotic diseases and various cancers.
— The only drug that has ever shown any clinically meaningful (not just lab biomarker) benefit for NASH (prevention of varices), testing to repeat these results in the NASH-RX trial.
— Appears to reduce the side effects of cancer immunotherapy in the MRK Keytruda combo trial. Next readout in Q2.
— Upcoming hepatic impairment (HI) biomarker results will guide the potential launch to additional indications.
— Chairman and largest shareholder is the multi-billionaire founder/owner of ULINE. It’s his passion. His long time exec is now the GALT CEO and he has a board member from his family wealth office.
— GALT CEO is taking 80% of his pay in the form of stock.
— HC Wainwright $12 price target.
— Multiple shots on goal include multiple indications + combo therapy possibility for each indication (drug has excellent safety profile).
— BMY stated in a patent filed last year that the Gal3 inhibitor is proven to work for cancer immunotherapy. So we know that BMY is knowledgeable/ has their eyes on this.
— Finished converting all preferred shares to common shares last year (historically, this is typically done for buy-in or buyout scenarios).
Increasing volume with solid support, as GALT enters 2021 catalysts.
GALT
Due Diligence Cliff's Notes:
— Leading inhibitor under development for Galectin-3, key native immune system protein involved in numerous inflammatory and fibrotic diseases and various cancers.
— The only drug that has ever shown any clinically meaningful (not just lab biomarker) benefit for NASH (prevention of varices), testing to repeat these results in the NASH-RX trial.
— Appears to reduce the side effects of cancer immunotherapy in the MRK Keytruda combo trial. Next readout in Q2.
— Upcoming hepatic impairment (HI) biomarker results will guide the potential launch to additional indications.
— Chairman and largest shareholder is the multi-billionaire founder/owner of ULINE. It’s his passion. His long time exec is now the GALT CEO and he has a board member from his family wealth office.
— GALT CEO is taking 80% of his pay in the form of stock.
— HC Wainwright $12 price target.
— Multiple shots on goal include multiple indications + combo therapy possibility for each indication (drug has excellent safety profile).
— BMY stated in a patent filed last year that the Gal3 inhibitor is proven to work for cancer immunotherapy. So we know that BMY is knowledgeable/ has their eyes on this.
— Finished converting all preferred shares to common shares last year (historically, this is typically done for buy-in or buyout scenarios).
